Patents Assigned to Eleven Biotherapeutics, Inc.
  • IL-6 antagonists and uses thereof
    Patent number: 9951130
    Abstract: Interleukin 6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 24, 2018
    Assignee: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • Nucleic acid encoding chimeric IL-1 receptor type I antagonists
    Patent number: 9458216
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 4, 2016
    Assignee: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • IL-6 ANTAGONISTS AND USES THEREOF
    Publication number: 20150125468
    Abstract: IL-6 antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.
    Type: Application
    Filed: October 7, 2014
    Publication date: May 7, 2015
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Thomas M. Barnes, David V. Erbe, Eric Steven Furfine, Alison Tisdale
  • PURIFIED PROTEINS
    Publication number: 20140341843
    Abstract: The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions.
    Type: Application
    Filed: July 27, 2012
    Publication date: November 20, 2014
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Gregory Zarbis-Papastoitsis, Emily Belcher Schirmer, Gary L. McNeil, Kathryn Golden
  • VARIANT SERUM ALBUMIN WITH IMPROVED HALF-LIFE AND OTHER PROPERTIES
    Publication number: 20140315817
    Abstract: The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.
    Type: Application
    Filed: November 18, 2012
    Publication date: October 23, 2014
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Michael March Schmidt, Eric Steven Furfine, Amy Jada Andreucci, Thomas M. Barnes
  • CHIMERIC CYTOKINE FORMULATIONS FOR OCULAR DELIVERY
    Publication number: 20140308239
    Abstract: Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 16, 2014
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Gregory Zarbis-Papastoitsis, Patricia Lowden, Byeong Chang
  • Chimeric IL-1 receptor type I antagonists
    Patent number: 8853150
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: October 7, 2014
    Assignee: Eleven Biotherapeutics, Inc.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS
    Publication number: 20130209396
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Application
    Filed: July 29, 2011
    Publication date: August 15, 2013
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • TREATING SURFACE OF THE EYE DISORDERS
    Publication number: 20130195868
    Abstract: Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition.
    Type: Application
    Filed: June 23, 2011
    Publication date: August 1, 2013
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventor: Burt A. Adelman
  • IL-17 FAMILY CYTOKINE COMPOSITIONS AND USES
    Publication number: 20130064788
    Abstract: Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.
    Type: Application
    Filed: October 11, 2010
    Publication date: March 14, 2013
    Applicants: Eleven Biotherapeutics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas M. Barnes, Michael M. Schmidt, Bracken M. King, K. Christopher Garcia, Sashank Reddy, Gregory James Sieczkiewicz, Lauren K. Ely